Biomerica (NASDAQ:BMRA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Biomerica (NASDAQ:BMRA) announced its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03), Fidelity Earnings reports. Biomerica had a negative return on equity of 40.08% and a negative net margin of 52.42%.

BMRA stock traded down $0.35 during midday trading on Friday, hitting $5.71. The company’s stock had a trading volume of 4,579 shares, compared to its average volume of 1,687,348. Biomerica has a 12 month low of $2.05 and a 12 month high of $23.39. The firm has a market capitalization of $67.11 million, a price-to-earnings ratio of -17.66 and a beta of -0.47. The company has a 50 day moving average of $5.75 and a two-hundred day moving average of $7.05.

In other news, Director Catherine Coste bought 9,100 shares of the stock in a transaction dated Monday, October 26th. The stock was purchased at an average cost of $5.45 per share, for a total transaction of $49,595.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 23.70% of the company’s stock.

A number of analysts have commented on BMRA shares. Colliers Securities started coverage on shares of Biomerica in a report on Tuesday, November 10th. They set a “buy” rating and a $13.00 target price for the company. B. Riley reduced their price objective on shares of Biomerica from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Aegis reduced their price objective on shares of Biomerica from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, October 19th.

Biomerica Company Profile

Biomerica, Inc, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.

Featured Article: Sell-Side Analysts

Earnings History for Biomerica (NASDAQ:BMRA)

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.